Focused On-demand Library for Trafficking protein particle complex subunit 9

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

NIK- and IKBKB-binding protein; Tularik gene 1 protein

Alternative UPACC:

Q96Q05; Q4VTT3; Q658K7; Q6P149; Q6ZQT3; Q7L5C4; Q86Y21; Q96SL2; Q9BQA2


Trafficking protein particle complex subunit 9, also known as NIK- and IKBKB-binding protein or Tularik gene 1 protein, plays a pivotal role in cellular processes. It functions as an activator of NF-kappa-B through increased phosphorylation of the IKK complex, which is crucial for immune response and cell survival. Additionally, it may contribute to neuronal cells differentiation and vesicular transport from the endoplasmic reticulum to Golgi, highlighting its importance in cellular trafficking and signaling.

Therapeutic significance:

The protein's involvement in Intellectual developmental disorder, autosomal recessive 13, characterized by below average intellectual functioning and cerebral white matter hypoplasia, underscores its therapeutic potential. Understanding the role of Trafficking protein particle complex subunit 9 could open doors to potential therapeutic strategies for treating intellectual developmental disorders and improving cognitive function.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.